10-Q: IR-Med Inc. Reports Q1 2025 Results, Citing Progress in PressureSafe Commercialization and DiaSafe Development Amidst Going Concern Uncertainty

IR-Med Inc. announces its Q1 2025 financial results, highlighting advancements in its PressureSafe and DiaSafe devices while acknowledging substantial doubt about its ability to continue as a going concern.

Summary

• IR-Med Inc. reported a net loss of $773,000 for the three months ended March 31, 2025, compared to a net loss of $657,000 for the same period in 2024.
• The company's cash and cash equivalents stood at $51,000 as of March 31, 2025, with current liabilities of approximately $617,000.
• Management expresses substantial doubt about the company's ability to continue as a going concern, with current cash resources expected to be sufficient only through the second quarter of 2025.
• IR-Med is focusing on the commercial launch of its PressureSafe device and the development of its DiaSafe device for diabetic foot ulcers.
• The company received an advance payment of approximately $171,468 from the Israeli Innovation Authority (IIA) to fund the development of the DiaSafe device.
• IR-Med entered into an Equity Purchase Agreement with Williamsburg Venture Holdings for up to $15 million over a 24-month period.
• The company issued 1,000,000 shares of common stock to Williamsburg Venture Holdings as consideration for the Equity Purchase Agreement.
• IR-Med issued unsecured convertible promissory notes for an aggregate amount of $31,200 to three individuals.
• The company's board of directors approved the extension of the expiration date of 3,636,634 warrants until June 30, 2025, subject to warrant holder approval.
• A lawsuit filed against the company in 2023, alleging breach of contract, remains unresolved after mediation failed.

Sentiment

Score: 3

Explanation: The sentiment is low due to the company's increasing losses, limited cash resources, and going concern uncertainty, despite some positive developments in product development and funding.

Positives

• The company received FDA listing certification for its PressureSafe device, a Class I device, on April 9, 2024.
• The company is preparing for the commercial launch of PressureSafe, with initial sales planned during the second half of 2025.
• The company received an advance payment of approximately $171,468 from the IIA to fund the development of the DiaSafe device.
• The Equity Purchase Agreement with Williamsburg Venture Holdings could provide up to $15 million in funding over 24 months.
• The company's board of directors approved the extension of the expiration date of 3,636,634 warrants until June 30, 2025, subject to warrant holder approval.

Negatives

• The company incurred a net loss of $773,000 for the three months ended March 31, 2025.
• The company's cash and cash equivalents stood at $51,000 as of March 31, 2025, with current liabilities of approximately $617,000.
• Management expresses substantial doubt about the company's ability to continue as a going concern, with current cash resources expected to be sufficient only through the second quarter of 2025.
• A lawsuit filed against the company in 2023, alleging breach of contract, remains unresolved after mediation failed.

Risks

• The company's limited cash resources raise substantial doubt about its ability to continue as a going concern.
• The company's ability to execute its business plan is dependent on securing additional financing.
• The company faces risks common to the medical device industry, including regulatory approvals, market acceptance, and competition.
• The ongoing lawsuit could result in significant financial liabilities.
• The Iron Swords war could have a negative impact on global and regional conditions and may adversely affect the company's business, financial condition, and results of operations.

Future Outlook

The company plans to continue development and marketing of its products and is seeking additional financing arrangements. Management expects to continue to incur significant expenses and operating losses as its product matures for distribution. Initial sales of PressureSafe are planned for the second half of 2025.

Management Comments

• Management expresses substantial doubt about the company's ability to continue as a going concern.
• Management's plans include continued development and marketing of the company's products, as well as seeking additional financing arrangements.

Industry Context

The company operates in the medical device industry, focusing on point-of-care decision support devices. The global diagnostics market is driven by solutions that can be applied in healthcare settings. The company's initial focus is on the development of decision support system solutions utilizing its proprietary platform for the pre-emptive diagnosis of PIs, and diabetic foot ulcers.

Comparison to Industry Standards

• It is difficult to compare IR-Med's results directly to industry standards due to its early stage and focus on specific niche markets within medical devices.
• Comparable companies developing similar non-invasive diagnostic tools include those in the digital health and remote patient monitoring sectors.
• Companies like Senseonics (continuous glucose monitoring) and Livongo (diabetes management) offer insights into market adoption and challenges for innovative medical technologies.
• However, IR-Med's specific focus on pressure injuries and diabetic foot ulcers differentiates it from broader diagnostic companies.

Management Changes

Legal Proceedings

• A lawsuit was filed against the Company, the Subsidiary and Mr. Aharon Klein in the Tel Aviv District Court of Israel by an individual who provided, on a part time basis, certain consulting services to the Subsidiary between October 2015 through October 2016, prior to the acquisition of the Subsidiary by the Company.
• The lawsuit alleges breach of contract by the defendants based on non-payment of amounts purportedly owed to the plaintiff in respect of the services rendered, including the market value of the Company's common stock that the plaintiff alleges should have been issued to him in respect of his services.
• The suit seeks declaratory judgment that the defendants breached certain agreements with the plaintiff and claimed damages in the aggregate amount of approximately $2.1 million based on the current exchange rate between the U.S. Dollar and the Israeli NIS.
• Mediation sessions were held in January 2025, and April 2025.
• The parties informed the honorable court on April 23, 2025, of the failure of the mediation process.
• The Company believes that the allegations are baseless and without merit.
• The Company intends to vigorously defend its rights.

Related Party Transactions

• Effective March 26, 2025, the company entered into a Note Purchase Agreement with Mr. Ran Ziskind, Mr. Yaniv Cohen, and Mr. Oded Bashan for an aggregate amount of $31,200.

Stakeholder Impact

• Shareholders face potential dilution from equity offerings and the Equity Purchase Agreement.
• Employees face uncertainty due to the company's financial instability and potential cost-cutting measures.
• Customers and partners face uncertainty regarding the company's ability to deliver on its product development and commercialization plans.
• Creditors face increased risk of non-payment due to the company's limited cash resources.

Next Steps

• Continue development and marketing of the company's products.
• Seek additional financing arrangements.
• Prepare for the commercial launch of PressureSafe.
• Continue development of DiaSafe.
• Comply with regulatory and reporting obligations related to the IIA grant.
• Vigorously defend the company's rights in the ongoing lawsuit.

Key Dates

Keywords

IR-Med, PressureSafe, DiaSafe, Financial Results, Q1 2025, Medical Device, FDA, IIA, Equity Purchase Agreement, Going Concern